Antibe Therapeutics (ATE) Competitors

C$0.30
0.00 (0.00%)
(As of 05/16/2024 ET)

ATE vs. RVX, AEZS, APS, MBX, BCT, HBP, and WLLW

Should you be buying Antibe Therapeutics stock or one of its competitors? The main competitors of Antibe Therapeutics include Resverlogix (RVX), Aeterna Zentaris (AEZS), Aptose Biosciences (APS), Microbix Biosystems (MBX), BriaCell Therapeutics (BCT), Helix BioPharma (HBP), and Willow Biosciences (WLLW). These companies are all part of the "medical" sector.

Antibe Therapeutics vs.

Antibe Therapeutics (TSE:ATE) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Antibe Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Resverlogix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Resverlogix has lower revenue, but higher earnings than Antibe Therapeutics. Antibe Therapeutics is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Antibe TherapeuticsC$9.71M1.61-C$18.24M-C$0.35-0.84
ResverlogixN/AN/A-C$16.74M-C$0.08-0.75

Resverlogix received 121 more outperform votes than Antibe Therapeutics when rated by MarketBeat users. Likewise, 84.01% of users gave Resverlogix an outperform vote while only 74.41% of users gave Antibe Therapeutics an outperform vote.

CompanyUnderperformOutperform
Antibe TherapeuticsOutperform Votes
189
74.41%
Underperform Votes
65
25.59%
ResverlogixOutperform Votes
310
84.01%
Underperform Votes
59
15.99%

Antibe Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. Comparatively, Resverlogix has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.

In the previous week, Resverlogix had 3 more articles in the media than Antibe Therapeutics. MarketBeat recorded 3 mentions for Resverlogix and 0 mentions for Antibe Therapeutics. Resverlogix's average media sentiment score of 0.82 beat Antibe Therapeutics' score of 0.00 indicating that Resverlogix is being referred to more favorably in the news media.

Company Overall Sentiment
Antibe Therapeutics Neutral
Resverlogix Positive

Resverlogix's return on equity of 0.00% beat Antibe Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Antibe TherapeuticsN/A -52.72% -19.13%
Resverlogix N/A N/A -44.23%

Summary

Resverlogix beats Antibe Therapeutics on 9 of the 11 factors compared between the two stocks.

Get Antibe Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATE vs. The Competition

MetricAntibe TherapeuticsBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$15.64MC$237.29MC$5.17BC$5.47B
Dividend YieldN/A3.48%44.01%5.54%
P/E Ratio-0.84109.95118.4523.84
Price / Sales1.6114,893.162,367.412,190.61
Price / Cash0.6111.7136.4579.74
Price / Book0.606.375.753.25
Net Income-C$18.24M-C$25.28MC$105.79MC$293.63M
7 Day PerformanceN/A0.06%1.39%1.54%
1 Month PerformanceN/A4.77%4.28%4.15%
1 Year Performance-42.16%3.93%7.71%26.85%

Antibe Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RVX
Resverlogix
0 of 5 stars
C$0.06
flat
N/A-53.8%C$16.47MN/A-0.7519News Coverage
Gap Down
AEZS
Aeterna Zentaris
0 of 5 stars
C$11.60
+4.9%
N/A+201.3%C$14.04MC$4.50M-0.6211News Coverage
Gap Up
High Trading Volume
APS
Aptose Biosciences
0 of 5 stars
C$1.65
+4.4%
N/A+147.7%C$26.81MN/A-0.1631News Coverage
MBX
Microbix Biosystems
0 of 5 stars
C$0.32
-5.9%
N/A-20.5%C$43.97MC$22.42M10.67N/AAnalyst Revision
High Trading Volume
BCT
BriaCell Therapeutics
0 of 5 stars
C$2.86
-4.3%
N/AN/AC$45.70MN/A-2.6516Gap Up
HBP
Helix BioPharma
0 of 5 stars
C$0.21
-8.7%
N/A-4.5%C$48.18MN/A-7.009Gap Up
WLLW
Willow Biosciences
0 of 5 stars
C$0.09
flat
N/A-28.0%C$10.79MC$1.17M-0.8519News Coverage

Related Companies and Tools

This page (TSE:ATE) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners